SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-068593
Filing Date
2021-03-04
Accepted
2021-03-04 08:58:02
Documents
16
Period of Report
2021-03-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d77427d8k.htm   iXBRL 8-K 50746
2 EX-2.1 d77427dex21.htm EX-2.1 424263
3 EX-99.1 d77427dex991.htm EX-99.1 34312
7 GRAPHIC g77427g0304121927926.jpg GRAPHIC 3675
8 GRAPHIC g77427g0304121928098.jpg GRAPHIC 2754
  Complete submission text file 0001193125-21-068593.txt   765469

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA fprx-20210304.xsd EX-101.SCH 3071
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE fprx-20210304_lab.xml EX-101.LAB 17372
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fprx-20210304_pre.xml EX-101.PRE 10953
9 EXTRACTED XBRL INSTANCE DOCUMENT d77427d8k_htm.xml XML 3283
Mailing Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 415-365-5600
FIVE PRIME THERAPEUTICS, INC. (Filer) CIK: 0001175505 (see all company filings)

IRS No.: 260038620 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36070 | Film No.: 21712698
SIC: 2834 Pharmaceutical Preparations